Nanobac Prarmaceuticals
Seite 1 von 1 Neuester Beitrag: 17.08.06 23:28 | ||||
| Eröffnet am: | 20.12.04 21:28 | von: joker67 | Anzahl Beiträge: | 19 |
| Neuester Beitrag: | 17.08.06 23:28 | von: horstpaul | Leser gesamt: | 4.899 |
| Forum: | Hot-Stocks | Leser heute: | 3 | |
| Bewertet mit: |  | |||
Good luck!
greetz joker
Optionen
| Boardmail an "joker67" |
Wertpapier: Nanobac Pharmaceuticals |
Optionen
| Boardmail an "joker67" |
Wertpapier: Nanobac Pharmaceuticals |
Optionen
| Boardmail an "joker67" |
Wertpapier: Nanobac Pharmaceuticals |
Müsst Ihr gucken hier:
About Nanobac Life Sciences
Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Nanobacterium sanguineum (Nanobacteria). The Company's pioneering research is establishing the pathogenic role of Nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit http://www.nanobacsciences.com.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.
So,aber mehr schreibe ich jetzt hier nicht,jetzt ist Jungchen dran.:-)
Optionen
| Boardmail an "joker67" |
Wertpapier: Nanobac Pharmaceuticals |
Optionen
| Boardmail an "joker67" |
Wertpapier: Nanobac Pharmaceuticals |
Hallo an alle Arivaner.
Meine Frage an Euch: Was sagt ihr zu Nanobac Pharmaceuticals Inc (NNBP.OB)?
Die Firma beschäftigt sich mit Nanobakteriellen Infektionen und Verkalkungen in den Gefässen die durch Nanobakterien entstehen. Anfangs eher belächelt wurde mittlerweile auch offiziell in Fachpublikationen bestätigt das es Nanobakterien gibt.
Desweiteren hat die Firma das Buch "The Calcium Bomb" herausgebracht das nun bereits in zweiter Auflage erschienen ist.
Somit scheint das Thema auch in Fachkreisen auf breites Interesse zu stossen.
Weitere Informationen auch auf: http://finance.yahoo.com/q?s=NNBP.OB
Meiner Meinung nach hat die Aktie großes Potential und ist noch nicht "entdeckt".
Irgendwo hab ich auch mal gelesen das es die einzige Firma ist die sich mit Nanobakterien beschäftigt.
Die Aktie scheint zumindest schon einen starken Boden gebildet zu haben.
Mittlerweile ist diese Aktie auch kein Pink Sheet mehr und dürfte daher auch für eine breitere Schicht von Anlegern interessant werden. (zumindest auch aus charttechnischer Sicht)
Über Meinungen zu NNBP.OB würde ich mich freuen.
Gruß
freisein
Das war dann wohl ein kurzes Gastspiel bei Ariva für dich.
Pech gehabt.
Optionen
| Boardmail an "joker67" |
Wertpapier: Nanobac Pharmaceuticals |
greetz joker
Optionen
| Boardmail an "joker67" |
Wertpapier: Nanobac Pharmaceuticals |
...Nanobac has previously announced published research that demonstrated the role nanobacteria play in the production of electricity. A fuel cell was used to enrich a microbial consortium generating electricity...."
WEDNESDAY, MAY 03, 2006 11:50 AM
- BusinessWire
TAMPA, Fla., May 03, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced that Inflammatory nanoparticles that produce calcified deposits like those found in arthritic joints have been cultured from the synovial fluid of rheumatoid arthritis and osteoarthritis patients by Japanese researchers, as reported in the Journal of Proteome Research.
"This is the first report to indicate that human synovial fluids contain Nanobacteria-like particles," the study notes.
The study, Nanobacteria-Like Particles in Human Arthritic Synovial Fluids, by T. Tsurumoto, T. Matsumoto, A. Yonekura, and H. Shindo, Department of Orthopaedics, Graduate School of Biomedical Sciences, Nagasaki University, supports the existence and pathogenic role of nanobacteria-like particles found in human diseases such as heart, prostate and kidney disease by Mayo Clinic and other researchers.
In a two year experiment, calcifying nanoparticles were cultured from the joint fluid of each participating patient, demonstrating that 100 percent of patients had the particles.
The experiment was based on methods pioneered by Nanobac Scientists, Drs. Neva Ciftcioglu and Olavi Kajander.
"After about 2 months of culture, nanoparticles appeared in the synovial fluids from all the patients to greater or lesser degrees," the study found. "These nanoparticles gradually increased in number and in size."
Medical researchers have often theorized about the presence of a calcifying agent that generates associated painful inflammation in arthritis, but until now had never found one.
Nanobacteria produce a calcium phosphate material known as calcification, which is shown in many studies, and cited in the Merck Manual of Diagnosis and Therapy, as provoking inflammation.
"If self-proliferating nanoparticles exist in mammalian synovial fluids and membranes, then they may have an effect on many joint diseases," the study's authors concluded.
"This is another example of independent researchers finding nanobacteria in patients with a specific disease condition," said Nanobac Co-Chairman Dr. Benedict Maniscalco, Fellow of the American College of Cardiology (FACC).
"It shows the value of our research, which is the only work to explain how calcification occurs in diseases afflicting most of the aging population," Dr. Maniscalco added.
The findings come on the heels of a paper published in the World Journal of Urology by Cleveland Clinic researcher Dr. Daniel Shoskes and Dr. Hadley M. Wood, which concluded that nanobacteria-like particles may play a ubiquitous role in prostate disease.
Another independent paper published earlier this year in the journal Urology Research by Khullar et al reports induction of renal calcification by nanobacteria.
Disclosure statement: Nanobac Pharmaceuticals did not fund the arthritis or Khullar studies, so the findings are independent.
http://bigcharts.marketwatch.com/news/...827211&symb=NNBP&sid=1501681
In discussing the conference call, John Stanton, Chairman of Nanobac Pharmaceuticals Inc., stated, "We have a commitment to our shareholders as well as the investment community for high level disclosure and communication, and for that reason we are looking forward to discussing our progress and developments with our shareholders and the investment community. We look forward to updating interested parties on recent developments."
Interested parties may hear the conference call by telephone.
Instructions for hearing the conference call:
To hear the conference call as it takes place:
Call 800-434-1335 in the United States or Canada or;
Call 404-920-6442 Internationally
Pin Code: 39548527
Exclusive:
For Expedited Entry into the Conference, please register at this
link for your Direct Access 800 number:
http://www.AccuConference.com/NNBP
To hear a recording of the call (available for 30 days immediately
following the conference call):
Call 800-428-6220 in the United States or Canada;
Call 404-920-6443 Internationally
Pin Code: 39548527
Quelle:
http://bigcharts.marketwatch.com/news/...112915&symb=NNBP&sid=1501681
Nanobac Pharmaceuticals and Fetzer Memorial Trust Enter Groundbreaking Collaboration to Photograph Never before Seen Calcification Mechanism
TUESDAY, AUGUST 08, 2006 9:48 AM
TAMPA, Fla., Aug 08, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced it has entered into a collaboration agreement with the Fetzer Memorial Trust to photograph the replication cycle of disease-related calcifying particles (also known as nanobacteria or Calcifying Nanoparticles), using light microscopes to break the 200 nanometer ("nm") resolution barrier. The breakthrough allows Nanobac scientists to determine if calcification, which occurs in most diseases on the leading causes of death list, has a biological mechanism, which would make it susceptible to therapy. Results could generate new approaches to the treatment of calcifying diseases such as heart disease, kidney stones and diabetes, and validate the significance of related Nanobac diagnostics and therapies.
"Until now, scientists had to 'fix' or inactivate such nanoparticles to see below the 200 nm threshold using electron microscopy," explained Nanobac's Co-Chairman and Research Group head, Dr. Benedict Maniscalco. "Now we can photograph the replication cycle without inactivating the particles. This is essential because some have a replication time of days rather than minutes or hours, which rendered electron microscopy ineffective for this purpose."
The technology was developed at Auburn University and is marketed by Aetos Technologies. The "CytoViva"(TM) microscope system is capable of resolving details at or below 100 nm and of detecting particles as small as 50 nm, representing a significant improvement over conventional light microscopes. The CytoViva(TM) system was selected in June by R&D Magazine as one of the top 100 most technologically significant products introduced to the marketplace in 2006. This international award is often referred to as the 'Oscar of Inventions.'
Calcifying nanoparticles have been isolated by many researchers in diseases ranging from atherosclerosis to kidney stones, but support for research into therapies against these particles has been hampered by lack of visual proof that the particles self-replicate. "Since the 1980s scientists have tried to photograph replication of calcifying nanoparticles, without success," Dr. Maniscalco added, "Now we have the tools to do it, thanks to the innovative approach of the Fetzer Memorial Trust."
The Fetzer Memorial Trust has supported development of this technology for many years, and has made arrangements for Nanobac to use one of a very few available microscopes. The research is being done by Nanobac scientists at Nanobac laboratories located at the NASA Johnson Space Center Astrobiology Laboratories in Houston, Texas, as part of Nanobac's recently announced new core research priorities. The microscope is currently located in Nanobac's labs and work has begun. Initial results are expected by year-end. Nanobac has the exclusive right to intellectual property resulting from discoveries about calcifying nanoparticles in this research project.
Nanobac Pharmaceuticals Inc. Announces Independent Study That Shows Nanobacteria Promote Gallstones
THURSDAY, AUGUST 10, 2006 9:57 AM
TAMPA, Fla., Aug 10, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced the publication by independent researchers of a proof of concept that calcifying nanoparticles, also known as nanobacteria, promote disease.
The company also announced it is initiating a project to validate the findings in its own experiments, to be completed by year-end 2006.
In "An Animal Model of Black Pigment Gallstones Caused by Nanobacteria" published in the June edition of the peer-reviewed journal Digestive Diseases and Sciences, Dr. Limin Wang et al from Shantou University Medical College, Guangdong, China, established that calcifying nanoparticles cause black pigment gallstones in rabbits when injected into the gallbladder. The study concludes, "We successfully cultured nano-sized particles coated with hydroxyapatite from human gallbladder bile and confirmed that they were nanobacteria by their typical growth rates, optical properties, specific stainability with Hoechst 33258, and by immunologic methods. By the animal experiment, we demonstrated for the first time that black pigment gallstones could be promoted by nanobacterial infection."
Previously no-one has shown a cause of black pigment gallstones. This type of gallstone accounts for 10-15 percent of all gallstones in humans and afflicts millions of people worldwide annually.
"This finding shows that calcifying particles provoke disease in an animal model," said Nanobac Co-Chairman Dr. Benedict Maniscalco. "It establishes these particles as infectious agents that are closely tied to calcification diseases which afflict tens of millions of people. The study leaves no doubt that these particles play a central role in disease and merit a broad investigation by the medical and scientific community," he added.
The study was conducted independent of Nanobac Pharmaceuticals and was not funded from any corporate source. The company has committed funding to a project to validate the study findings. Work is expected to begin this month and be completed by year-end 2006. Nanobac is the only company with regulatory approval of diagnostics that can accurately identify these calcifying particles. The company is also expecting to start a clinical trial on a promising therapy for such stone-forming diseases by the fourth quarter of 2006.
Abstract of the study is now available at PubMed by entering the study title at this website: [url]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed[/url]
Quelle diese news
Quelle vorherige news
...Shareholders and Interested Parties
TAMPA, Fla., Aug 16, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (NNBP) ("Nanobac" or "The Company") today provided the following updates:
The Company recently filed its 10Q for the quarter ending June 30, 2006. Company CEO John Stanton stated, "I want to take this opportunity to highlight a few matters and set the course for future actions and expectations.
"As you're probably aware from recent news releases by Nanobac, the Company has sharpened its focus now that its intellectual property is consolidated and we are beginning to receive more results from our research.
"Cover stories in major news media have made it clear that inflammation and calcification are among the most prevalent and unsolved disease conditions on the 'leading causes of death list.' Inflammation and calcification occur in heart disease, breast cancer, and stone-forming diseases such as kidney stones and prostatitis.
"More than 20,000 published medical papers refer to calcification. Until now no one has identified a definite cause of the deposits, so imagine the impact on medicine of being able to show a cause, as well as the capability to diagnose and treat pathological calcification effectively.
"What has excited us at Nanobac recently is the independent findings published by scientists at well-known institutions, supporting what our own scientists have maintained for years: that the type of calcification generated by nanobacteria (Calcifying Nanoparticles or CNPs as they are also known) is a cause of inflammation, and a contributor to the damaging deposits found in those diseases.
"That is precisely our focus at Nanobac, and here are the main areas of our revitalized R&D program:
-- Therapy. The Company is entering into agreements to test its proprietary drug combination against stone-forming diseases, with a preliminary focus on prostatitis, which affects millions of men and is largely untreatable today, along with other stone forming diseases such as gallstones and kidney stones. Contracts have been entered into and we expect the first part of the trial to begin in the third quarter of 2006.
-- Proving Infection. The gold standard for proving that something is infectious is "Koch's postulates." In June of 2006, a new study published by independent scientists in a peer reviewed journal demonstrated key elements of Koch's postulates by showing that CNPs are implicated in formation of black pigment gallstones in an animal model. Until now there was no known cause of such gallstones that affect millions of persons. Nanobac is now entering into an agreement to validate this finding with the same scientists. Work will begin immediately. We are very excited about this landmark finding.
-- Identifying Infection Mechanisms. The Company has preliminary photographic and biochemical evidence that calcifying nanoparticles self-replicate, suggesting that they have a self-sustaining mechanism and might be infectious. In a new agreement with the Fetzer Memorial Trust, Nanobac recently began an experiment at its own laboratories at NASA in Houston to demonstrate this replication via time-lapse photography, using new award-winning CytoViva microscope technology capable of breaking through the 200 nanometer (nm) barrier for light microscopes. Our Scientific Director at the Johnson Space Center has very recently obtained proof of concept that this can be done, by taking preliminary photographs of CNPs at never-before-seen magnifications for real-time photography. Nanobac owns all IP arising from this particular experiment.
-- Thrombosis is the cause of death in most hemodialysis patients. The Company intends to validate its findings that calcifying nanoparticles discovered in human blood provoke thrombosis and might be preventable.
-- Diagnostics. The Company believes it has identified precisely what its proprietary Elisa antibody test is uniquely recognizing on calcifying nanoparticles, and has begun validating this finding.
"You can expect more information on these initiatives in the near future and results by early 2007.
"We have fortified our findings with patents to protect our exclusive capacities for diagnosis and therapy. The objection period for our nanobacteria eradication patent has expired without objections being filed, thus providing another valuable tool to turn our scientific findings into profits for our shareholders."
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.
Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
SOURCE: Nanobac Pharmaceuticals Inc.
Nanobac Pharmaceuticals Inc., Tampa
Douglas Mulhall, 813-262-9025
dmulhall@nanobaclabs.com
or
Redwood Consultants, LLC
415-884-0348
InvestorInfo@RedwoodConsultants.com